186 related articles for article (PubMed ID: 29509243)
1. Targeting histone deacetylases in endometrial cancer: a paradigm-shifting therapeutic strategy?
Garmpis N; Damaskos C; Garmpi A; Spartalis E; Kalampokas E; Kalampokas T; Margonis GA; Schizas D; Andreatos N; Angelou A; Lavaris A; Athanasiou A; Apostolou KG; Spartalis M; Damaskou Z; Daskalopoulou A; Diamantis E; Tsivelekas K; Alavanos A; Valsami S; Moschos MM; Sampani A; Nonni A; Antoniou EA; Mantas D; Tsourouflis G; Markatos K; Kontzoglou K; Perrea D; Nikiteas N; Kostakis A; Dimitroulis D
Eur Rev Med Pharmacol Sci; 2018 Feb; 22(4):950-960. PubMed ID: 29509243
[TBL] [Abstract][Full Text] [Related]
2. Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma.
Psilopatis I; Pergaris A; Giaginis C; Theocharis S
Dis Markers; 2021; 2021():7850688. PubMed ID: 34804263
[TBL] [Abstract][Full Text] [Related]
3. Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers.
Singh BN; Zhou H; Li J; Tipton T; Wang B; Shao G; Gilbert EN; Li Q; Jiang SW
Future Oncol; 2011 Dec; 7(12):1415-28. PubMed ID: 22112317
[TBL] [Abstract][Full Text] [Related]
4. A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells.
Takai N; Ueda T; Nishida M; Nasu K; Narahara H
Int J Mol Med; 2006 Feb; 17(2):323-9. PubMed ID: 16391833
[TBL] [Abstract][Full Text] [Related]
5. Cytostatic and apoptotic effects of DNMT and HDAC inhibitors in endometrial cancer cells.
Xu S; Ren J; Chen HB; Wang Y; Liu Q; Zhang R; Jiang SW; Li J
Curr Pharm Des; 2014; 20(11):1881-7. PubMed ID: 23888960
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells.
Dowdy SC; Jiang S; Zhou XC; Hou X; Jin F; Podratz KC; Jiang SW
Mol Cancer Ther; 2006 Nov; 5(11):2767-76. PubMed ID: 17121923
[TBL] [Abstract][Full Text] [Related]
7. The Role of Histone Deacetylase Inhibitors in Uveal Melanoma: Current Evidence.
Moschos MM; Dettoraki M; Androudi S; Kalogeropoulos D; Lavaris A; Garmpis N; Damaskos C; Garmpi A; Tsatsos M
Anticancer Res; 2018 Jul; 38(7):3817-3824. PubMed ID: 29970501
[TBL] [Abstract][Full Text] [Related]
8. Anticancer effect of histone deacetylase inhibitor scriptaid as a single agent for hepatocellular carcinoma.
Liu L; Sun X; Xie Y; Zhuang Y; Yao R; Xu K
Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29945926
[TBL] [Abstract][Full Text] [Related]
9. Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.
Damaskos C; Garmpis N; Valsami S; Kontos M; Spartalis E; Kalampokas T; Kalampokas E; Athanasiou A; Moris D; Daskalopoulou A; Davakis S; Tsourouflis G; Kontzoglou K; Perrea D; Nikiteas N; Dimitroulis D
Anticancer Res; 2017 Jan; 37(1):35-46. PubMed ID: 28011471
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of histone deacetylases in endometrial carcinoma: involvement of histone deacetylase 2 in the proliferation of endometrial carcinoma cells.
Fakhry H; Miyamoto T; Kashima H; Suzuki A; Ke H; Konishi I; Shiozawa T
Hum Pathol; 2010 Jun; 41(6):848-58. PubMed ID: 20178884
[TBL] [Abstract][Full Text] [Related]
11. A novel class I histone deacetylase inhibitor, I-7ab, induces apoptosis and arrests cell cycle progression in human colorectal cancer cells.
Yang L; Liang Q; Shen K; Ma L; An N; Deng W; Fei Z; Liu J
Biomed Pharmacother; 2015 Apr; 71():70-8. PubMed ID: 25960218
[TBL] [Abstract][Full Text] [Related]
12. Targeting Histone Deacetylases in Malignant Melanoma: A Future Therapeutic Agent or Just Great Expectations?
Garmpis N; Damaskos C; Garmpi A; Dimitroulis D; Spartalis E; Margonis GA; Schizas D; Deskou I; Doula C; Magkouti E; Andreatos N; Antoniou EA; Nonni A; Kontzoglou K; Mantas D
Anticancer Res; 2017 Oct; 37(10):5355-5362. PubMed ID: 28982843
[TBL] [Abstract][Full Text] [Related]
13. Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro.
Strobl JS; Cassell M; Mitchell SM; Reilly CM; Lindsay DS
J Parasitol; 2007 Jun; 93(3):694-700. PubMed ID: 17626366
[TBL] [Abstract][Full Text] [Related]
14. HDAC as a therapeutic target for treatment of endometrial cancers.
Ren J; Zhang J; Cai H; Li Y; Zhang Y; Zhang X; Zhao D; Li Z; Ma H; Wang J; Gao YE; Xiao L; Liu R; Qian J; Liu Y; Wei H; Li J
Curr Pharm Des; 2014; 20(11):1847-56. PubMed ID: 23888962
[TBL] [Abstract][Full Text] [Related]
15. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy.
Kong Y; Tannous P; Lu G; Berenji K; Rothermel BA; Olson EN; Hill JA
Circulation; 2006 Jun; 113(22):2579-88. PubMed ID: 16735673
[TBL] [Abstract][Full Text] [Related]
16. Scriptaid cause histone deacetylase inhibition and cell cycle arrest in HeLa cancer cells: A study on structural and functional aspects.
Janaki Ramaiah M; Naushad SM; Lavanya A; Srinivas C; Anjana Devi T; Sampathkumar S; Dharan DB; Bhadra MP
Gene; 2017 Sep; 627():379-386. PubMed ID: 28668345
[TBL] [Abstract][Full Text] [Related]
17. Scriptaid, a novel histone deacetylase inhibitor, enhances the response of human tumor cells to radiation.
Kuribayashi T; Ohara M; Sora S; Kubota N
Int J Mol Med; 2010 Jan; 25(1):25-9. PubMed ID: 19956898
[TBL] [Abstract][Full Text] [Related]
18. M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells.
Takai N; Ueda T; Nishida M; Nasu K; Narahara H
Gynecol Oncol; 2006 Apr; 101(1):108-13. PubMed ID: 16263156
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin.
Uchida H; Maruyama T; Nagashima T; Asada H; Yoshimura Y
Endocrinology; 2005 Dec; 146(12):5365-73. PubMed ID: 16123169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
